Levetiracetam

May be taken with or without food. Oral soln may be taken directly or diluted in a glass of water.

Hypersensitivity.

Patient with QTc-interval prolongation, pre-existing cardiac disease, electrolyte disturbances. The total daily dose and administration frequency should be the same or maintained when switching between oral and IV form. Avoid abrupt withdrawal. Renal and severe hepatic impairment. Children. Pregnancy and lactation. Patient Counselling This drug may cause somnolence, fatigue or coordination difficulties; if affected, do not drive or operate machinery. Monitoring Parameters Assess renal function before starting treatment especially in patients with severely impaired hepatic function. Monitor therapeutic response (e.g. seizure activity, type, duration) at the start and throughout the treatment; diastolic blood pressure (in children 1 month to <4 years); signs and symptoms of CNS depression or hypersensitivity reaction. Observe for emergence or worsening of depression, suicidal thoughts, and unusual changes in mood or behaviour.

Significant: Suicidal ideation and behaviour; psychotic symptoms and behavioural abnormalities (e.g. irritability, aggressiveness); somnolence, fatigue, coordination difficulties; serious skin reactions (e.g. Stevens-Johnson syndrome, toxic epidermal necrolysis); increased blood pressure (in patients 1 month to <4 years). Rarely, acute kidney injury, decreased blood cell counts (e.g. agranulocytosis, leucopenia, neutropenia, thrombocytopenia, pancytopenia); exacerbated seizure frequency or severity; prolonged QT interval. Ear and labyrinth disorders: Vertigo. Gastrointestinal disorders: Abdominal pain, nausea, vomiting, diarrhoea, dyspepsia. General disorders and administration site conditions: Lethargy, asthenia. Infections and infestations: Influenza. Metabolism and nutrition disorders: Anorexia. Musculoskeletal and connective tissue disorders: Neck pain. Nervous system disorders: Headache, dizziness, balance disorder, tremor. Psychiatric disorders: Anxiety, depression, hostility, insomnia, nervousness. Respiratory, thoracic and mediastinal disorders: Nasopharyngitis, cough, pharyngitis, nasal congestion, pharyngolaryngeal pain. Skin and subcutaneous tissue disorders: Rash.
Potentially Fatal: Anaphylaxis or angioedema.

Increased serum concentration of methotrexate. May decreased the efficacy of oral levetiracetam when taken with osmotic laxative macrogol. May increase risk of QT interval prolongation with drugs affecting QTc-interval.

Anticonvulsants

N03AX14 - levetiracetam ; Belongs to the class of other antiepileptics.